8-K: Bausch Health Completes $1.6B Debt Exchange Offer

Bausch Health Companies Inc. successfully concluded its exchange offers for senior secured notes, issuing approximately $1.6 billion in new notes due 2032.

Summary

• Bausch Health Companies Inc. announced the final results and expiration of its offers to exchange outstanding 4.875% Senior Secured Notes due 2028 and 11.00% Senior Secured Notes due 2028.
• The exchange was for up to $1.6 billion aggregate principal amount of new 10.00% Senior Secured Notes due 2032, issued by its indirect wholly-owned subsidiary 1261229 B.C. Ltd.
• The offers expired at 5:00 p.m., New York City time, on December 23, 2025.
• An aggregate principal amount of $2.7 billion of Existing Senior Secured Notes was validly tendered and not withdrawn.
• Approximately $1,600 million principal amount of New Notes will be issued upon settlement, which is expected on December 26, 2025.
• For the 11.00% Notes due 2028, $1,519,477,000 principal amount was tendered, and $885,806,000 was accepted, resulting in $903,359,000 of new 10.00% Notes due 2032 being issued.
• For the 4.875% Notes due 2028, $1,170,539,000 principal amount was tendered, and $797,431,000 was accepted, resulting in $696,641,000 of new 10.00% Notes due 2032 being issued.
• Holders of accepted notes will also receive a cash amount for accrued interest, if applicable.

Sentiment

Score: 7

Explanation: The successful completion of the debt exchange offer, particularly the extension of debt maturities, is a positive step in managing the company's financial risk. However, the increase in interest rates for a portion of the exchanged debt introduces a negative aspect regarding future interest expenses. The overall sentiment is moderately positive due to improved debt maturity profile.

Positives

• Successfully completed the debt exchange offer, achieving the target of approximately $1.6 billion in new notes.
• Extended the maturity profile of a significant portion of its debt from 2028 to 2032, reducing near-term refinancing pressure.
• Reduced the interest rate for a portion of the exchanged debt (from 11.00% to 10.00%).

Negatives

• Increased the interest rate for a portion of the exchanged debt (from 4.875% to 10.00%), which will lead to higher interest expenses for those notes.

Risks

• Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those described.

Future Outlook

The filing primarily reports on the completion of a specific debt exchange transaction. It does not provide a broader future outlook for the company's operations or financial performance beyond the expected settlement of the offers on December 26, 2025.

Industry Context

This debt exchange reflects a common strategy for companies with significant debt loads to proactively manage their capital structure. By extending maturities, Bausch Health aims to alleviate near-term refinancing risks, a practice often observed in industries with high capital intensity or those undergoing strategic transformations. The mixed interest rate outcome (lower for some, higher for others) indicates a balance between maturity extension and cost of capital in the current market environment.

Comparison to Industry Standards

• The successful completion of a debt exchange offer, particularly one that extends maturities, is generally viewed positively in the pharmaceutical and healthcare industry, where companies often carry substantial debt for R&D, acquisitions, or operational scaling.
• Comparable companies like Teva Pharmaceutical Industries Ltd. or Mallinckrodt plc have also engaged in significant debt restructuring efforts to manage their leverage and improve their financial flexibility, often involving similar exchange offers to push out maturities.
• The interest rate of 10.00% for the new senior secured notes due 2032 is indicative of the company's credit profile and prevailing market conditions for high-yield debt, which can be higher than for investment-grade pharmaceutical peers but potentially competitive within its specific credit rating segment.

Stakeholder Impact

• Shareholders: Reduced near-term refinancing risk and improved debt maturity profile could positively impact investor confidence.
• Existing Noteholders (participating): Exchanged their 2028 notes for new 2032 notes, altering their investment's maturity and interest rate profile.
• Existing Noteholders (non-participating): Their 2028 notes remain outstanding, potentially becoming a smaller, less liquid tranche.

Next Steps

• Settlement of the exchange offers is expected to occur on December 26, 2025.

Key Dates

Recommendation

The successful debt exchange is a positive for Bausch Health as it extends a significant portion of its debt maturities, reducing immediate refinancing pressure. This improves the company's financial flexibility. However, the increase in interest rates for a portion of the exchanged debt (from 4.875% to 10.00%) will lead to higher interest expenses, which is a negative. Given these offsetting factors, the filing suggests a 'hold' recommendation as the company is actively managing its debt, but the overall financial impact is mixed, not providing a strong catalyst for a 'buy' or 'sell' based solely on this event.

Keywords

Debt Exchange, Senior Secured Notes, Bausch Health, Refinancing, Corporate Finance, Bond Exchange, Liability Management